Description: Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Home Page: vcel.com
VCEL Technical Analysis
64 Sidney Street
Cambridge,
MA
02139
United States
Phone:
617 588 5555
Officers
Name | Title |
---|---|
Mr. Dominick C. Colangelo Esq. | CEO, Pres & Director |
Mr. Joseph Anthony Mara Jr. | CFO & Treasurer |
Mr. Michael Halpin | Chief Operating Officer |
Mr. Sean C. Flynn | Sr. VP, Gen. Counsel & Sec. |
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer |
Mr. Jonathan Siegal | Principal Accounting Officer, VP & Corp. Controller |
Mr. Eric Burns | Exec. Director of Financial Planning and Analysis & Investor Relations |
Mr. Patrick J. Fowler | Sr. VP of Corp. Devel. & Strategy |
Ms. Heidi Hassen | VP of HR |
Mr. Roland DeAngelis | Sr. VP of Commercial Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 370.3704 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 6.3809 |
Price-to-Sales TTM: | 6.8909 |
IPO Date: | 1997-02-04 |
Fiscal Year End: | December |
Full Time Employees: | 281 |